INTRODUCTION
In recent years a number of fascinating advances have been made in the field of tissue-engineering of the gastrointestinal tract. A partial or complete loss of any part of the alimentary tract, from esophagus to anus, is debilitating and potentially lifethreatening. Severe truncation of the small intestine is particularly devastating. A loss of absorptive surface area of 70-75% results in significant impairment of both metabolic and physiologic function that cannot be overcome by compensatory adaptation. This is referred to as short bowel syndrome (SBS) and may be secondary to conditions such as midgut volvulus, gastroschisis, necrotizing enterocolitis, inflammatory bowel disease (IBD) and cancer. SBS sequelae include severe dehydration, carbohydrate, protein, mineral and vitamin deficiencies as well as renal and biliary calculi, failure to thrive and death [1] . The incidence of SBS in children is 24.5 per 100 000 live births and it carries a 5-year mortality of 30% [2, 3] .
Treatment is often a combination of medical therapy with nutritional supplements, total parenteral nutrition (TPN), lifestyle modification or attempts at surgical correction with gastrointestinal reconstruction, bowel lengthening or transplant. These management strategies are associated with several complications, such as TPN-related liver disease and central line sepsis [4] . Transplantation of the small bowel, although improving, is associated with rejection, lifelong immunosuppression, donor scarcity and high cost [5] . These issues highlight why tissue-engineering is so appealing. Researchers seek the possibility of replacing lost organs with tissue that is equivalent in structure and function
SMALL INTESTINE
The epithelial surface of normal intestine is organized in crypts and villi. The villi provide enhanced surface area for the secretory (goblet and enteroendocrine cells) and absorptive cells (enterocytes) necessary for the digestion and absorption of proteins, lipids, carbohydrates, nutrients and minerals. The crypts are occupied by crypt-based columnar cells (CBCCs) and Paneth cells. Paneth cells produce antimicrobial compounds important for host defense and maintenance of gastrointestinal barrier. The stem cell is responsible for the production of self-renewing daughter cells as well as the progenitor cells that differentiate to mature epithelial cells [6] .
There is ongoing debate regarding the location of the stem cell. Some theorize that it is confined to the crypt base, whereas others suggest it exits in a position that averages four cells upward from the crypt base, referred to as cell position 4 (cp4). Historically, Cheng and Leblond [7] were the first to suggest that differentiated intestinal epithelial cells arose from the CBCC, based on the interpretation of electron micrographs and lineage tracing. It was later observed that the earliest, immature Paneth cells are present in position 5, but mature as they migrate downward toward the crypt. The other epithelial cells also first appeared in position 5, but migrate upward toward the villus tip [8] . Cell migration studies to determine rate and mechanism by which epithelial cells travel along the cryptvillus axis supported the theory that the small intestinal stem cell is located (on average) at cp4 [6, [9] [10] [11] . This dichotomy has been an area of intensive research.
Identification of the intestinal stem cell has been hampered by the lack of a definitive marker. The Clevers lab, of the Hubrecht Institute, established the leucine-rich-repeat-containing Gprotein-coupled receptor 5 (Lgr5) as a putative stem cell marker. Wingless integration (WNT) is a highly conserved signaling pathway involved in development, differentiation and proliferation. Unlike other WNT target genes that were expressed in multiple cell types, the Lgr5 gene was expressed in the crypts of the small intestine, but was absent in the villi. The expression pattern was clearly confined to the CBCCs that are intermingled with the Paneth cells. Subsequent lineage tracing demonstrated that these Lgr5-expressing CBCCs could generate all cell types of the intestinal epithelium [12] . Interestingly, when single Lgr5 cells were isolated and cultured in vitro with epidermal growth factors (EGFs) R-spondin 1 and Noggin, they grew to produce crypt-villus structures with fully differentiated epithelial cells at an efficiency of 6% (i.e. 6% of single cells in this culture system grew to produce crypt-villus structures) [13] . Therefore, it has been shown that the cell marked by Lgr5 (the CBCC) is capable of pluripotent differentiation and is, therefore, a stem cell.
Although growing crypt-villus structures from single Lgr5 cells in vitro is possible without a supporting mesenchymal tissue niche, this culture system required the aforementioned growth factors. Although the mesenchymal niche may not be needed for cellular differentiation per se, the growth factors it produces are necessary [6] . Recently, the co-culture of Paneth cells with Lgr5 increased the efficiency of crypt-villus formation from 6 to 77%, suggesting the ability of Paneth cells to support the growth of Lgr5 stem cells [14 && ]. In contradistinction, Sangiorgi and Capecchi [15] demonstrated that cells expressing Bmi1 (a member of Polycomb group genes first described as a proto-oncogene in lymphoma, but observed in normal intestinal tissue) are located predominantly at cp4, are capable of self-renewal and pluripotency, and are required for crypt maintenance. Ablation of Lgr5-expressing cells in mice did not disrupt the integrity of intestinal epithelium. Rather, it was observed that the progeny of Bmi1-expressing cells
KEY POINTS
Recent evidence supports the theory that intestinal homeostasis is maintained by two populations of intestinal stem cells, a rapidly dividing population that is marked by expression of Lgr5 and located interspersed with the Paneth cells in the crypt base and a quiescent population, marked by expression of Bmi1, that is located, on average, at cell position 4 from the base of the crypt.
Partial or complete loss of any segment of the gastrointestinal system is currently managed with medications, parenteral nutrition, bowel elongation surgery and/or intestinal transplantation, which can be life-saving, but is also associated with many complications.
Tissue-engineering by means of cellular seeding of a biodegradable scaffold with subsequent intraperitoneal or subcutaneous implantation has been applied to every organ of the alimentary tract to generate fullthickness, syngeneic tissue that may someday be used to restore normal gastrointestinal function to patients.
increased and that these cells led to the repopulation of Lgr5-expressing cells. One hypothesis is that Bmi1-expressing cells mark quiescent stem cells located at cp4, whereas Lgr5-expressing cells represent a population of rapidly cycling stem cells in the crypt base [16 && ]. Additional candidates for stem cell markers have been explored, including Doublecortin and CaM kinase-like-1 (DCAMKL-1), mouse telomerase reverse transcriptase (mTert), CD133 and Musashi-1 [15, [17] [18] [19] [20] .
To enhance the study of drug transport, cell signaling, and response to infection, systems for culturing tissue-engineered intestinal epithelium have been developed. Human Caco-2 cells (a colonic adenocarcinoma cell line) have been co-cultured with human microvascular endothelial cells on decellularized porcine intestine in a three-dimensional bioreactor. This system produces enterocytes that more closely model native enterocyte drug transport than routine monolayer culture systems [21 & ]. Salerno-Goncalves et al. In addition to the in-vitro growth of engineered epithelium, full-thickness tissue-engineered small intestine (TESI) has been grown in vivo. The Vacanti group of Massachusetts General Hospital used a variation of a technique described by Evans et al. to grow TESI in a Lewis rat model. Intestinal biopsies were digested into multicellular clusters with preserved mesenchymal and epithelial association, termed organoid units. The organoid units were seeded onto a biodegradable artificial polymer and implanted into the omenta of host rats and later harvested for histologic examination [24, 25] . This technique has recently been transitioned to the mouse, granting access to the transgenic tools of this species to design experiments aimed at deciphering the mechanism of TESI growth [26 && ]. After harvest of murine TESI, low and high magnification of hematoxylin and eosin staining demonstrates a fully differentiated mucosal lining with normal-appearing crypts and villi, as depicted in Fig. 1 ]. In addition to mucosal elements, TESI also possesses intestinal subepithelial myofibroblasts (ISEMFs). As their name suggests, these cells are located immediately deep to the epithelium and can be found along the entire length of the alimentary tract. They offer a protective, fenestrated cover adjacent to the epithelium. These cells are thought to support mucosal growth via interaction with the intestinal stem cell, and participate in wound healing and intestinal immunity. Notably, TESI contains blood vessels, nerve and muscle of donor origin. These mesenchymal and nerve components are necessary for normal structure and function [26 && ]. To determine the function of TESI in Lewis rats, two experimental groups were compared. The first underwent massive enterectomy alone, whereas a second group underwent massive enterectomy with anastomosis of TESI. The TESI group was shown to have significantly improved postoperative weight 
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and B12 absorption, suggesting a potential role for TESI in the management of SBS [1] . To validate this technique in a model that more closely approximates the size of the neonate, TESI has been grown in the Yorkshire swine. These animals underwent intestinal biopsy, organoid units production and autologous implantation at a single operation. This confirms the feasibility of performing this technique in a realistic clinical scenario that also limits the risk of contamination or cell transformation possible with in-vitro cultures [27] . In a separate study on rabbits and pigs, bowel elongation with interposition of an acellular dermal matrix failed to develop neointestine, proving that anastomosis of a scaffold alone will not encourage ingrowth of new intestine [28 & ].
ESOPHAGUS
Loss of esophageal length to malignancy, caustic ingestion or long-gap esophageal atresia is commonly treated by a variety of surgical techniques. Esophageal replacement via gastric pull-through or intestinal interposition provides a conduit for the passage of food and liquids. Unfortunately, these replacements are functionally inferior to native esophagus. Tissue-engineered esophagus (TEE) has been grown by culturing oral keratinocytes and fibroblasts from beagles on human amniotic membrane. This culture is sheeted onto tubularized polyglocolic acid (PGA) with smooth muscle tissue and implanted into the omenta of dogs. Later, the TEE can be transferred on a vascular pedicle into the thorax to replace a 3-cm surgically created gap in the esophagus. The animals followed out to 420 days continue to demonstrate passage of food from mouth to stomach without problems. Although these segments do not display peristalsis, proximal movement propels food through the adynamic segment [29] . Similar attempts to produce TEE have proven successful in sheep. Ovine esophageal epithelial cells (OEECs) have been isolated and cultured in vitro, and then seeded onto collagen scaffolds. The cultured epithelial cells can be tubularized around a stent and implanted into the omenta of host lamb. When removed, the engineered constructs possess a luminal side lined by patches of esophageal epithelium with vascular ingrowth of the outer perimeter [30 & ,31 & ].
In an attempt to identify the optimum scaffold and epithelial source for the growth of TEE, Green et al. [32 & ] performed a systematic assessment using four different scaffolds (human esophageal matrix, porcine matrix, human dermal matrix, and collagen) and two epithelial cell types (human esophageal squamous cells and an immortalized human esophageal epithelial cell line, Het-1A). They concluded that human esophageal squamous cells seeded onto a porcine esophageal matrix most reliably recapitulate a normal, wellattached, stratified epithelium [32 & ].
STOMACH
Gastric cancer accounts for 700 000 deaths worldwide each year, making it the second leading cause of cancer-related mortality, and is the most common indication for total gastrectomy [33] . Gastric resection with gastrointestinal reconstruction lacks the reservoir capacity and gastric physiology of native stomach. Using a rat model, tissue-engineered stomach (TES) produced from organoid units seeded onto a biodegradable scaffold and implanted into the omentum produced a well-vascularized, muscular stomach lined with mucosa that could be used as a successful replacement of native stomach [34, 35] . Using a similar technique, rats with TES replacing their native stomach were compared with a control group that had undergone gastrectomy and Roux-en-Y reconstruction without TES. When harvested at 24 weeks, staining revealed that the TES possessed a mucosal lining, smooth muscle-like layers, parietal cells, and G cells. The TES group was less anemic, but there was no difference in body weight, total protein or cholesterol levels between the two groups [36] .
As is the case with the small intestine, Lgr5-expressing cells in the stomach, present at the base of corpus and pyloric glands, are self-renewing and multipotent. Single Lgr5-positive cells can be cultured in vitro with enriched media to produce organoids that are reminiscent of mature pyloric epithelium [37 && ]. In a rat model, patches of tissueengineered stomach could be harvested, frozen and later used to repair large area defects of the stomach wall, suggesting a potential role in gastric reconstruction [38 & ]. Notably, Speer et al. [39 && ] were successful in transitioning TES into a murine model. Mouse TES demonstrates fully differentiated gastric epithelium with mucous, enteroendocrine, chief and parietal cells in addition to the expression of the stem cell markers, Dcamkl-1 and Lgr5. Using the transgenic tools available in mice, it may be possible to elucidate the genetic mechanism of TES growth, allowing researchers to improve this process and expedite translation to human therapy [39 && ].
LARGE INTESTINE AND ANUS
Surgical resection of the large intestine and/or anus is associated with alterations in the enterohepatic circulation, stool microbiology and absorption.
Quality of life is decreased by permanent ileostomy, increased stool frequency or stool incontinence. The Vacanti lab has demonstrated that tissue-engineered colon (TEC) resembles native colon architecture [40] . Rats with TEC demonstrated 1.5 times greater weight gain, longer stool transit time, decreased stool moisture content, and higher total serum bile acids. Moreover, rats without TEC were hyponatremic with increased serum urea nitrogen [41] .
Restoration of fecal continence with a tissueengineered internal anal sphincter (IAS) is of particular interest. Using a mouse model, IAS smooth muscle cells may be removed by microdissection, stripped of connective tissue and seeded onto a fibrin mold. These cells grow in vitro and selfalign into a ring. The ring was implanted subcutaneously into a mouse, developing into a bioengineered IAS capable of generating basal tone, relaxation and contraction [42 & ,43 & ]. Growth of IAS may be optimized by the addition of osmotic pumps dispensing growth factors. A comparison of fibroblast growth factor-2 (FGF2), vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) demonstrated that they all improve growth and neovascularization. VEGF and PDGF provide the greatest improvement in basal tonic force of the bioengineered IAS [44 & ]. Co-culture of human IAS smooth muscle with immortomouse fetal enteric neurons has been implanted into mice to produce human-bioengineered IAS [45 & ]. In the near future, it may be possible to fully engineer human colon and anus for the restoration of normal stooling patterns.
CONCLUSION
The alimentary tract is a highly specialized organ system and a loss of any segment carries devastating and potentially life-threatening sequelae. Medical and surgical treatments are often suboptimal. In-vitro descriptions of stem cell mechanism and tissue-engineered mucosa provide a foundation upon which a tissue-engineering strategy is developed and improved. Overall, the goal is to grow full-thickness tissue, in vivo, that offers restoration of normal function from the patient's autologous, syngeneic tissue. The developments described here have advanced the field of tissue-engineering of the gastrointestinal tract, and translation to human therapy is on the horizon. 
